Tocainide detailed information

Tocainide detailed information

Gene therapy
Clinical data
ATC code	C01BB03 (WHO)
Physiological data
Legal status
Pharmacokinetic data
Bioavailability	0.9-1 (oral)
Protein binding	10-20%
Metabolism	glucuronidation (primary)
Elimination half-life	9-14 R, 13-20 S
Excretion	30-50% urine (unchanged)
Identifiers
IUPAC name 2-amino-N-(2,6-dimethylphenyl)-propanamide
CAS Number	41708-72-9
PubChem Template:Abbreviation	38945
DrugBank	APRD01266
Chemical and physical data
Formula	C11H16N2O
Molar mass	192.258 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Tocainide (Tonocard®) is a class Ib antiarrhythmic agent. It is no longer sold in the United States.

Quick look at the Pharmacokinetics

Tocaine is a lidocaine analog, that does not have significant 1st pass metabolism. It is found in two enantiomers. The R isomer is 4x as potent as the S. Oral bioavaliability is 0.9-1.0. In the blood tocainide is 10-20% protein bound. The Volume of distribution is 2.5-3.5 L/kg. 30-50% is excreted unchanged in the urine. The more active R-isomer is cleared faster in anephric patients or those with severe renal dysfunction. The main metabolite is the glucuronidated tocainide carbamic acid. The glucuronosyl transferase is apparently induced by rifampin. Weak inhibition of Cyp1A2 leads to a mild theophylline interaction. (Not verbatim)

External links

• Template:MedlinePlusDrugInfo

Burton ME. Applied Pharmacokinetics & Pharmacodynamics: Principles of Therapeutic Drug Monitoring. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.

Template:Antiarrhythmic agents